Wczytywanie spółki
Just reported
Q3 2026 results
From Neurocrine Biosciences's results release of 2 listopada 2026; its quarterly report has since been filed.
Revenue
Actual
1,12B USD
+41% y/y
+17% q/qGuided
—
No guide given
EPS, GAAP
Actual
1,96 USD
-3,9% y/y
+41% q/qGuided
—
No guide given
Operating income, GAAP
Actual
331,3M USD
+39% y/y
+119% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Neurocrine Biosciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited33,9B USDA
ELANElanco Animal Health Incorporated13,3B USDA
KNSAKiniksa Pharmaceuticals International, plc8,2B USDA+
LQDALiquidia Corporation5,2B USDA
BHCBausch Health Companies Inc.3,1B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
BIIBBiogen Inc.28 paź 2026BAGraded B, now A
Pełne sprawozdania finansowe →
Zbudowane z własnych raportów spółki Neurocrine Biosciences, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
